Clinical Trials
12 trialsNCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT00003225 2020-08-03
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT03545711 2018-08-06
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT00003344 2018-05-16
Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer
Medical University of South Carolina
Phase 1/2 Completed
NCT02575508 2016-05-20
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT00551421 2015-03-31
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00004870 2013-02-21
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00005818 2013-01-23
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00217711 2012-06-05
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Swiss Cancer Institute
Phase 1/2 Completed